【摘要】 目的评价长效干扰素(Peg-IFN-α-2 a)联合利巴韦林治疗慢性丙型肝炎(CHC)的临床疗效及安全性。方法 56例慢性丙型肝炎患者随机被分为试验组(n=29)和对照组(n=27)。其中试验组给予Peg-IFN-α-2 a联合利巴韦林治疗;对照组给予IFN-α-2 a联合利巴韦林治疗。治疗时间均为48周,随访时间24周。分别检测治疗前、用药48周及停药24周的病毒学、生化学、基因分型,比较2组间治疗结果以及ALT、HCV RNA定量及病毒学应答情况。结果试验组患者用药48周及停药24周总应答率均明显高于对照组(P均<0.01)。不同基因完全应答率比较,只有HCV基因型1感染者在治疗48周后及随访24周后时间之间存在显著性差异(P<0.01),其余各组间比较均无显著性差异(P均>0.05)。HCV RNA定量的水平对于对照组和治疗组的病毒学完全应答情况均无显著性影响(P均>0.05)。主要不良反应包括流感样综合征、贫血、中性白细胞减少及血小板减少等,但不影响临床用药。结论慢性丙型肝炎患者使用长效干扰素Peg-IFN-α-2 a联合利巴韦林治疗,其疗效明显好于干扰素IFN-α-2 a联合利巴韦林治疗,患者不良反应未显著增加。更多还原

【Abstract】 Objective It is to investigate the effect and safety of peginterferon alfa-2a combined with ribavirin in patients with chronic hepatitis C.Methods Fifty-six patients with chronic hepatitis C were randomly divided into test group(n=29) and control group(n=27).Patients in control group were assigned interferon alfa-2a plus ribavirin,and in test group were administered peginterferon alfa-2a plus ribavirin.Effect was assessed by measuring hepatitis C virus(HCV) RNA before treatment,and for 48 weeks,and following a 24-week treatment-free period.Results The overall response rates(VR) in test group were significantly higher than control group at 48 weeks and following a 24-week treatment-free period(both P<0.01).Comparison between different genotypes,there were significant differences only in complete response between after 48 weeks of treatment and follow-up time of 24 weeks in HCV genotype 1 infected patients(P<0.01).There was no significant difference among the other groups(P>0.05).The RNA quantitative level of HCV had no significant impact on the virological complete response in control group and test group(P>0.05).The major side effects included flu-like syndrome,anemia,neutropenia and thrombocytopenia,but which did not affect the clinical use of drugs.Conclusion For patients with chronic hepatitis C,the combination of peginterferon alfa-2a plus ribavirin is the most effective therapy.更多还原